Is Vitamin D One of the Key Elements in COVID-19 Days?

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)

Resveratrol is a polyphenol that has been well studied and has demonstrated anti-viral and anti-inflammatory properties that might mitigate the effects of COVID-19. Outpatients (N = 105) were recruited from central Ohio in late 2020. Participants were randomly assigned to receive placebo or resveratrol. Both groups received a single dose of Vitamin D3 which was used as an adjunct. The primary outcome measure was hospitalization within 21 days of symptom onset; secondary measures were ER visits, incidence of pneumonia, and incidence of pulmonary embolism. Five patients chose not to participate after randomization. Twenty-one-day outcome was determined of all one hundred participants (mean [SD] age 55.6 [8.8] years; 61% female). There were no clinically significant adverse events attributed to resveratrol. Outpatients in this phase 2 study treated with resveratrol had a lower incidence compared to placebo of: hospitalization (2% vs. 6%, RR 0.33, 95% CI 0.04-3.10), COVID-19 related ER visits (8% vs. 14%, RR 0.57, 95% CI 0.18-1.83), and pneumonia (8% vs. 16%, RR 0.5, 95% CI 0.16-1.55). One patient (2%) in each group developed pulmonary embolism (RR 1.00, 95% CI: 0.06-15.55). This underpowered study was limited by small sample size and low incidence of primary adverse events consequently the results are statistically similar between treatment arms. A larger trial could determine efficacy.Trial Registrations: ClinicalTrials.gov NCT04400890 26/05/2020; FDA IND #150033 05/05/2020.

Association of vitamin D deficiency with COVID-19 severity and mortality in Iranian people: a prospective observational study

Background

As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate, it is important to identify the prognostic factors related to increased mortality and disease severity. To assess the possible associations of vitamin D level with disease severity and survival, we studied 248 hospitalized COVID-19 patients in a single center in a prospective observational study from October 2020 to May 2021 in Tehran, Iran.

Methods

Patients who had a record of their 25-hydroxyvitamin D level measured in the previous year before testing positive with COVID-19 were included. Serum 25-hydroxyvitamin D level was measured upon admission in COVID-19 patients. The associations between clinical outcomes of patients and 25-hydroxyvitamin D level were assessed by adjusting for potential confounders and estimating a multivariate logistic regression model.

Results

The median (interquartile range) age of patients was 60 years (44–74 years), and 53% were male. The median serum 25-hydroxyvitamin D level prior to admission decreased with increasing COVID-19 severity (P=0.009). Similar findings were obtained when comparing median serum 25-hydroxyvitamin D on admission between moderate and severe patients (P=0.014). A univariate logistic regression model showed that vitamin D deficiency prior to COVID-19 was associated with a significant increase in the odds of mortality (odds ratio, 2.01; P=0.041). The multivariate Cox model showed that vitamin D deficiency on admission was associated with a significant increase in risk for mortality (hazard ratio, 2.35; P=0.019).

Conclusions:

Based on our results, it is likely that deficient vitamin D status is associated with increased mortality in COVID-19 patients. Thus, evaluating vitamin D level in COVID-19 patients is warranted.

Tanning-Elicited Variations in the Ultraviolet Absorption Spectra of the Cutaneous Tissues: Skin Photobiology and Photomedicine Implications

When ultraviolet radiation is absorbed within the cutaneous tissues, it can trigger a number of phenomena that can have detrimental or beneficial consequences to an individual's health. Tanning is among the most visually noticeable of these phenomena. It may result in significant changes in skin pigmentation and thickness. These spectrally-dependent physiological responses, in turn, can elicit variations in the ultraviolet absorption profiles of the cutaneous tissues and, consequently, alter the occurrence of other ultraviolet-induced photobiological processes such as the breaking of DNA strands and the synthesis of previtamin D3. These tanning-elicited variations in the cutaneous tissues' absorption profiles is often tied to the increased presence of melanin throughout these tissues. However, during the tanning, shifts in the relative content of this pigment within certain skin layers can also be observed. In particular, the stratum basale, the innermost epidermal layer where melanogenesis takes place, can have its relative melanin content significantly reduced in comparison with other epidermal layers. Since the aforementioned photobiological phenomena are preferentially brought about within this layer, such pigmentation shifts may have a more pivotal role in skin photobiology than has been assumed to date. Accordingly, in this work, we investigate the impact of spectrally-dependent tanning-elicited physiological responses, with a particular focus on the inter-layer melanin distribution patterns, on the absorption profiles of the main cutaneous tissues. We also examine how variations in these absorption profiles may alter the outcomes of photo-triggered phenomena associated with the onset of different medical conditions. Our findings are expected to contribute to the advance of the current understanding about skin photobiology, which is indispensable for the success of photomedicine initiatives involving this highly complex organ.